Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar) from NMPA (CFDA) to Treat NSCLC
Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination with Sintilimab & IBI305 in China
Shots:
- The BLA is based on two P-III study results assessing efficacy, safety and PK of IBI-305 vs bevacizumab in patients with advanced non-sq NSCLC and has demonstrated in meeting 1EPs with bio-similarity
- Innovent has received three NMPA acceptance including IBI-305 namely Tyvyt (sintilimab injection) and IBI-303 (adalimumab, biosimilar) in H2’18 for ankylosing spondylitis (AS), rheumatoid arthritis (RA) & psoriasis and r/r classical Hodgkin’s lymphoma respectively
- Avastin’s biosimilar IBI-305 (bevacizumab) is an anti-VEGF mAb, involved in inhibiting PI3K-Akt/PKB & Ras-Raf-MEK-ERK pathways and targeted for NSCLC, colorectal cancer and other malignant tumors
Click here to read full press release/ article | Ref: PRNewswire | Image: China Knowledge